Shisuo Du

TL;DR: A case of NSCLC, who rapidly progressed during a trial combining palliative radiotherapy and pembrolizumab, is presented, representing a first-time report ofNSCLC-intrinsic PD-1 expression and a potential mechanism by which PD- 1 blockade may promote cancer growth.

TL;DR: This study provides strong preclinical evidence that radiation‐induced cardiotoxicity is modulated by thePD‐1 axis and that PD‐1 blockade should be administered with careful radiotherapy planning with an effort of reducing cardiac dose.

TL;DR: In this article , an immune cloaking mechanism for RT-activated, innate immune cGAS-STING and suggested that RT enhances hepatocellular carcinoma immunotherapy was identified.

TL;DR: UTMD is an effective adjunct when combined with radiotherapy to treat HCC, showing a 170% reduction in tumor growth 7 days post treatment and a 3.2X improvement in median survival time when radiotherapy was combined with UTMD.

TL;DR: It is feasible to use the SARRP platform to perform dosimetric planning and delivery of SBRT in mice with lung cancer, and allows for preclinical studies that provide a rationale for clinical trials involving S BRT, especially when combined with immunotherapeutics.